Abstract
A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.
| Original language | English |
|---|---|
| Pages (from-to) | 805-819 |
| Number of pages | 15 |
| Journal | CNS Drugs |
| Volume | 19 |
| Issue number | 10 |
| DOIs | |
| State | Published - Dec 1 2005 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Neuropsychology and Physiological Psychology
- Pharmacology
Cite this
COX-2 inhibitors as adjunctive therapy in schizophrenia : Rationale for use and evidence to date. / Riedel, Michael; Strassnig, Martin T; Schwarz, Markus J.; Müller, Norbert.
In: CNS Drugs, Vol. 19, No. 10, 01.12.2005, p. 805-819.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - COX-2 inhibitors as adjunctive therapy in schizophrenia
T2 - Rationale for use and evidence to date
AU - Riedel, Michael
AU - Strassnig, Martin T
AU - Schwarz, Markus J.
AU - Müller, Norbert
PY - 2005/12/1
Y1 - 2005/12/1
N2 - A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.
AB - A better understanding of the human immune system and its complex interactions has resulted in new insights into the pathoaetiological mechanisms of psychiatric disorders. As a result, new treatment options are being explored. Several findings suggest that an imbalanced immune response is involved in the pathophysiology of schizophrenia. COX-2 inhibitors are known to influence the immune system in a way that may redirect this imbalance. Based on these suggestions, the COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia. While the first trial using celecoxib as add-on therapy to an atypical antipsychotic showed a significant beneficial effect, recent studies demonstrated that this effect may be limited to patients with recent-onset schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=31344446924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31344446924&partnerID=8YFLogxK
U2 - 10.2165/00023210-200519100-00001
DO - 10.2165/00023210-200519100-00001
M3 - Article
C2 - 16185091
AN - SCOPUS:31344446924
VL - 19
SP - 805
EP - 819
JO - CNS Drugs
JF - CNS Drugs
SN - 1172-7047
IS - 10
ER -